Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | SCN1A | P35498 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimenoxadol SCHEMBL2886211 | 0.99 | CYP3A4 (0.70) | CYP3A4CYP2D6LMNAALDH1A1CHRM2 | |
| Dimenoxadol SCHEMBL79044 | 0.99 | CYP3A4 (0.70) | CYP3A4CYP2D6LMNAALDH1A1CHRM2 | |
| Dimenoxadol SCHEMBL5854258 | 0.97 | CYP3A4 (0.69) | CYP3A4CYP2D6LMNAALDH1A1CHRM2 | |
| Dimenoxadol SCHEMBL2204879 | 0.96 | CYP3A4 (0.67) | CYP3A4CYP2D6LMNAALDH1A1CHRM2 | |
| Denaverine SCHEMBL147346 | 0.85 | CYP3A4 (0.52) | CYP3A4CYP2D6LMNAALDH1A1CHRM2 | |
| Dimenoxadol SCHEMBL4580231 | 0.85 | CYP3A4 (0.55) | CYP3A4CYP2D6LMNAALDH1A1CHRM2 | |
| Pargeverine SCHEMBL2111437 | 0.85 | CYP3A4 (0.51) | CYP3A4CYP2D6LMNAALDH1A1CHRM2 | |
| Denaverine SCHEMBL9569397 | 0.84 | CYP3A4 (0.54) | CYP3A4CYP2D6LMNAALDH1A1CHRM2 | |
| Pargeverine SCHEMBL30728632 | 0.84 | CYP3A4 (0.53) | CYP3A4CYP2D6LMNAALDH1A1CHRM2 | |
| SCHEMBL27585378 | 0.83 | CYP3A4 (0.63) | CYP3A4CYP2D6LMNAALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6518 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20250319074-A1 | TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME | UNIV EAST CAROLINA (US) | 2025-10-16 | — | — | US | claimed |
| US-12383743-B2 | Treatment of addiction and dependency | TACA JR ARTURO C (US) | 2025-08-12 | — | — | US | claimed |
| US-20250228771-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-07-17 | — | — | US | claimed |
| EP-4581017-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | Biodol Therapeutics (FR) | 2025-07-09 | — | — | EP | claimed |
| EP-4565202-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-06-11 | — | — | EP | claimed |
| WO-2024254056-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | CATALENT ONTARIO LIMITED (CA) | 2024-12-12 | — | — | WO | claimed |
| US-12133922-B2 | Abuse resistant capsule | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2024-11-05 | — | — | US | claimed |
| US-20240288374-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation | 2024-08-29 | — | — | US | claimed |
| WO-2024172892-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation (US) | 2024-08-22 | — | — | WO | claimed |
| WO-1999013799-A1 | SYNERGISTIC ANALGESIC COMBINATION OF OPIOID ANALGESIC AND CYCLOOXYGENASE-2 INHIBITOR | EURO-CELTIQUE, S.A. (LU) | 1999-03-25 | — | — | WO | claimed |
| US-5866164-A | Composition and dosage form comprising opioid antagonist | ALZA CORPORATION (US) | 1999-02-02 | — | — | US | claimed |
| EP-0785775-A4 | MELT-EXTRUDED ORALLY ADMINISTRABLE OPIOID FORMULATIONS | EURO CELTIQUE SA (LU) | 1998-08-19 | — | — | EP | claimed |
| US-5654281-A | Inhibiting the development of tolerance to and/or dependence on an addictive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1997-08-05 | — | — | US | claimed |
| EP-0785775-A1 | MELT-EXTRUDED ORALLY ADMINISTRABLE OPIOID FORMULATIONS | Euroceltique S.A. (LU) | 1997-07-30 | — | — | EP | claimed |
| CN-1130352-A | Method for relieving pain by orally administering 24-hour sustained-release opioid dosage form capable of rapidly increasing initial blood concentration of patient | EURO CELTIQUE SA (LU) | 1996-09-04 | — | — | CN | claimed |
| WO-1996014058-A1 | MELT-EXTRUDED ORALLY ADMINISTRABLE OPIOID FORMULATIONS | EURO-CELTIQUE, S.A. (LU) | 1996-05-17 | — | — | WO | claimed |
| EP-0647448-A1 | Orally administrable opioid formulations having extended duration of effect | Euroceltique S.A. (LU) | 1995-04-12 | — | — | EP | claimed |
| EP-0608893-A1 | Inhibiting the development of tolerance to and/or dependence on an additive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-08-03 | — | — | EP | claimed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | claimed |